Mana Capital Acquisition Corp.

The presentation signals meaningful reimbursement and commercialization milestones for the de-SPAC company, with Medicare coverage determination and commercial payer pilots still in progress—key drivers for revenue ramp and the ~$175B combined TAM.

Nothing can be read from this document about what was communicated to stockholders — the accompanying material is not part of the captured text, so the filing establishes only that additional proxy materials were filed on that date.

All per-share history in this report is restated for the 1-for-30 split, so nothing here is comparable to figures published before May 2025 on a pre-split basis. This summary is drawn from the cover page and introductory notes; the financial statements are not covered here.

Seeking the same Nasdaq 20% authorisation for a third consecutive year tells a holder how this company funds itself: through repeated private issuances of convertible securities, each requiring shareholder consent because each exceeds a fifth of the share count. Approval hands management standing authority to issue below market in non-public transactions, and the cumulative effect across three such authorisations is the dilution former MAAQ holders have absorbed. Being preliminary, the terms may change before the definitive proxy.

This is the third consecutive annual meeting at which holders have been asked to lift the Nasdaq 20% cap for private placements - the company has made serial dilution an annual governance ritual rather than a one-off financing event. Each approval covers a fresh series of transactions, so the cumulative issuance across three years is far larger than any single vote suggests. The Mana Capital trust was released at the de-SPAC.

Seeking a second reverse split authorisation twelve months after the first means the prior approval either went unused or failed to hold the price above $1.00 - either way the stock has continued to fall. The company would go on to request Nasdaq 20% issuance approvals at the 2024 and 2025 annual meetings as well, so split authority and dilution authority alternate on an annual cycle. The Mana Capital trust was released at the de-SPAC.

What changed: Cardio Diagnostics Holdings (post-merger entity from MAAQ) filed an investor presentation detailing commercial progress including CMS final payment rate of $854/test (Dec 2025), first in-network coverage via Atlas Healthcare Physicians (June 2026), out-of-network billing capability (July 2026), and in-house CLIA lab operations reducing COGS ~30%. Why it matters: The presentation signals meaningful reimbursement and commercialization milestones for the de-SPAC company, with Medicare coverage determination and commercial payer pilots still in progress—key drivers for revenue ramp and the ~$175B combined TAM.

What changed: DEFA14A of Cardio Diagnostics Holdings, Inc. — definitive additional proxy materials filed August 7, 2026. The captured document consists of the Schedule 14A cover page identifying the registrant, the 'Definitive Additional Materials' box and the fee statement ('No fee required'); no substantive soliciting content appears in the text available here. Why it matters: Nothing can be read from this document about what was communicated to stockholders — the accompanying material is not part of the captured text, so the filing establishes only that additional proxy materials were filed on that date.(flagged for human review)

What changed: Q2 2026 10-Q of Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO). As of August 7, 2026 there were 2,959,469 shares of common stock outstanding. The introductory note states the company effected a 1-for-30 reverse stock split effective May 12, 2025, and that all issued and outstanding stock and per-share amounts in the report, together with the exercise prices and share numbers under its equity incentive plans and outstanding warrants, have been adjusted for that split for all prior periods presented. Why it matters: All per-share history in this report is restated for the 1-for-30 split, so nothing here is comparable to figures published before May 2025 on a pre-split basis. This summary is drawn from the cover page and introductory notes; the financial statements are not covered here.

What changed: Cardio Diagnostics Holdings, Inc. (the post-merger entity from Mana Capital Acquisition Corp.) filed a DEF 14A for its 2026 annual meeting on September 18, 2026, with a record date of July 31, 2026 and 2,959,469 shares outstanding. The proxy includes a proposal (No. 2) to approve the future issuance of shares equal to 20% or more of outstanding common stock in a non-public transaction to raise up to $10.0 million, consistent with similar proposals approved at the 2023, 2024, and 2025 annual meetings but never utilized. Why it matters: This filing confirms the post-merger company is operational and seeking continued shareholder authorization for potential dilutive capital raises, though it has relied on an ATM facility since early 2024. For SPAC trackers, it signals the de-SPAC entity is navigating ongoing capital needs and Nasdaq listing compliance rather than any new trust, extension, or redemption event.